Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
Drug discovery, development, and commercialization must become faster and more efficient to address humanity’s health needs. Sumitovant embodies the bold promise of combining technology and life-sciences expertise to drive innovation.
Our portfolio includes marketed products and a robust investigational pipeline addressing unmet patient needs in pediatrics, urology, oncology, women’s health, specialty respiratory and infectious diseases.
We are next-generation biopharma innovating for patient-first outcomes through an agile approach that centers on the patient throughout.
Formed in 2019, Sumitovant was founded through the strategic alliance between Roivant Sciences and Sumitomo Pharma, our parent company based in Japan. Backed by Sumitomo Pharma's industry expertise and resources, Sumitovant is uniquely equipped to fuel innovation across the portfolio and to progress robust development and commercialization efforts.
We are industry-leading experts in drug development, business, engineering, science, and technology. Together, we operate with data-driven insights, agility, and scientific rigor to advance therapies people need most.